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n analytical methodology for the simultaneous determination of seven pharmaceuticals and two
etabolites belonging to the non-steroidal anti-inﬂammatory drugs (NSAIDs) and analgesics therapeutic
roups was developed based on off-line solid-phase extraction and ultra-high performance liquid chro-
atography coupled to tandem mass spectrometry (SPE–UHPLC–MS/MS). Extraction conditions were
ptimized taking into account parameters like sorbent material, sample volume and sample pH. Method
etection limits (MDLs) ranging from0.02 to 8.18ng/Lwere obtained. Thismethodologywas successfully
pplied to the determination of the selected pharmaceuticals in seawater samples of Atlantic Ocean in
he Northern Portuguese coast. All the pharmaceuticals have been detected in the seawater samples,
ith pharmaceuticals like ibuprofen, acetaminophen, ketoprofen and the metabolite hydroxyibuprofen
eing the most frequently detected at concentrations that can reach some hundreds of ng/L. 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction
Pharmaceuticals have been recognized as important emerging
nvironmental contaminants [1], being their occurrence reported
n different environmental compartments, including surface waters
2], wastewaters [3], groundwater [4], soils [5] and, even drinking
ater [6], at trace levels (nanograms to few micrograms per liter).
harmaceuticals can be released into the environment either as
arent compounds or as metabolites; therefore monitoring stud-
es should include not only the parent compound but also their
etabolites and transformation products [7].
Non-steroidal anti-inﬂammatory drugs (NSAIDs) and analgesics
re among the pharmaceuticals most consumed worldwide, either
s prescribed or over-the-counter medicines. Thus, nowadays, they
re frequently detected in the environment, posing a risk to aquatic
rganisms [8]. For instance, cytological changes in liver, kidney and
ills of ﬁsh species were described when exposed to diclofenac
9,10], while ibuprofen affected the spawning process of Japanesekilliﬁsh [11]. Notwithstanding that regulatory guidance to assess
the presence of pharmaceuticals in the aquatic environment is giv-
ing the ﬁrst steps with the Directive 2013/39/EU [12], amending
the Water Framework Directive (2000/60/EC) and the directive
2008/105/EC, establishing the creation of a Watch list, which will
include three pharmaceuticals, namely the sex hormones 17alpha-
ethinylestradiol and 17beta-estradiol, and the NSAID diclofenac, in
order to gather monitoring data that will facilitate the determina-
tion of appropriate measures to establish the risk posed by these
kind of contaminants.
Advances in analytical technology have been a key factor for
the detection of pharmaceuticals, their metabolites, and trans-
formation products in environmental matrices [13]. Presently,
liquid chromatography coupled to tandem mass spectrometry
(LC–MS/MS) is the analytical techniqueof choice for thedetermina-
tion of pharmaceuticals in environmental samples, due to its high
selectivity and sensitivity, allowing the detection of compounds at
levels of just a fewng/Lor less [14]. At the same time, improvements
in HPLC technology have been made, and nowadays the trend goes
toward the use of ultra-high performance liquid chromatography
(UHPLC), which uses short, narrow bore columns, packed with par-
ticles with a lower diameter (sub-2m). UHPLC allows a faster
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tnalysis, better resolution and narrower peaks comparatively to
onventional HPLC methodologies [15].
Since pharmaceuticals are usually present in the aquatic envi-
onment at very low concentrations, sample preparation is a very
mportant step in order to improve detection sensitivity and elim-
nate matrix effects. Solid phase extraction (SPE) is still the most
ommonly used extraction technique, because it allows simul-
aneous pre-concentration of analytes and extract clean-up in
queous matrices [16,17].
Althoughdata on the presence of pharmaceuticals in the aquatic
nvironment is growing, the knowledge of their occurrence in
oastal areas is still very sparse, since most of research in marine
nalytical chemistry focuses on classical lipophilic target com-
ounds like organochlorine pesticides and polycyclic aromatic
ydrocarbons [18]. Nevertheless, a large uncertainty exists rela-
ively to the presence of a broad variety of pollutants in seawater,
ncludingpharmaceuticals. In fact, thereareonlya fewworks focus-
ng the study of these emerging contaminants in seawater, showing
rincipally the presence of antibiotics [19–21], NSAIDs [20,22–24],
sychiatric drugs [19,20,22,23], lipid regulators [20,22,24], X-ray
ontrast agents [19] and -blockers [20,22,23] in seawater.
The main objective of the present work was to develop an
nalytical method for the quantiﬁcation of pharmaceuticals in sea-
ater. Twelve relevant compounds were selected, embracing two
herapeutic classes (NSAIDs and analgesics), taking into account
heir consumption among Portuguese population [25] as well as
ata obtained in our previous studies [26,27] that pointed out
harmaceuticals like ibuprofen, diclofenac and acetaminophen, as
eing detected in Portuguese environment at levels able to pose an
cotoxicological risk for aquatic organisms (Table 1). Thedeveloped
ethod was successfully applied to seawater samples of Atlantic
cean collected in the Northern Portuguese coast.
. Experimental
.1. Reagents, solvents and materials
Ibuprofen (purity ≥98%), hydroxyibuprofen (VETRANALTM
rade), carboxyibuprofen (VETRANALTM grade), acetaminophen
purity ≥98%), p-aminophenol (purity ≥99%), acetaminophen glu-
uronide sodium salt (purity ≥98%), acetylsalicylic acid (purity
99%), naproxen (VETRANALTM grade), nimesulide, ketoprofen
purity ≥98%), diclofenac sodium salt and dipyrone (grade: ana-
ytical standard) were purchased from Sigma–Aldrich (Spain).
he isotopically labeled compound ibuprofen-d3 used as internal
tandard was also purchased from Sigma–Aldrich.
Acetonitrile and methanol (LC–MS grade) were supplied by
.T. Baker (Deventer, The Netherlands), hydrochloric acid 37% was
btained from Carlo Erba (Rodano, Italy), formic acid (purity ≥98%)
as obtained from Merck (Darmstadt, Germany), ammonia 25%
as obtained from Panreac (Barcelona, Spain), and ammonium
ydroxide solution was purchased from Sigma–Aldrich (Steinhein,
ermany). Deionised water was produced using an Elix appara-
us (Millipore, Molsheim, France) and ultra-pure water (resistivity
f 18.2M cm) using a Simplicity 185 system (Millipore, Mol-
heim, France). All chromatographic solventswere ﬁltered through
0.22m nylon membrane ﬁlter (Supelco, Bellefonte, PA, USA)
nd degassed for 15min in an ultrasonic bath (Sonorex Digital 10P,
andelin DK 255P, Germany).
Both individual stock standard and isotopically labeled internal
tandard solutions (at a concentration of 1000mg/L) were pre-
ared on a weight basis in acetonitrile, except for p-aminophenol,
cetaminophen glucuronide, naproxen, diclofenac and dipyrone,
hich were prepared in acetonitrile–methanol (50:50, v/v), since
hese substances are very slightly soluble in pure acetonitrile andfreely soluble in methanol [30]. For all pharmaceuticals stock
standard solutions were stored at −20 ◦C and renewed every six
months. In the case of p-aminophenol, a fresh stock standard solu-
tion was prepared monthly due to its limited stability.
Working standard solutions, containing all pharmaceuticals,
wereprepared in acetonitrile–ultra-purewater (30:70, v/v) bymix-
ing appropriate amounts of the stock solutions. These solutions
were prepared before each analytical run.
The cartridges used for solid phase extraction (SPE)were Strata-
X (200mg, 3mL), Strata X-AW (200mg, 3mL), Strata-X-A (200mg,
3mL) and Strata X-C (200mg, 3mL) from Phenomenex (USA).
2.2. Sample collection and pre-treatment
Seawater samples were collected in three beaches (Lec¸a
da Palmeira (41◦11′24.38′′ N, 8◦41′40.86′′ W), Matosin-
hos (41◦10′34.09′′ N, 8◦41′40.86′′ W) and Azul (Conchinha)
(41◦12′14.82′′ N, 8◦42′55.06′′ W)) located near Oporto in the
Northern Portuguese coast during the bathing season in July 2013.
All the beaches belong to Matosinhos municipality, where it is
located the second largest artiﬁcial Portuguese harbor (Leixões
harbor), an oil reﬁnery, and a WWTP that is designed to serve
80,000 population equivalents and has a primary and secondary
treatment operating by activated sludge. The treated WWTP
efﬂuents are directly discharged into the Atlantic Ocean. Lec¸a
River, a river that suffers a strong anthropogenic pressure, also
reaches the Atlantic Ocean in Matosinhos coastal area.
Beaches were selected according to the classiﬁcation of bathing
water quality, being beaches A (Lec¸a da Palmeira), B (Matosinhos),
andC (Azul (Conchinha)) classiﬁed as excellent, good, and sufﬁcient
bathing water quality, respectively [31]. Seawater samples were
collected in bottles previously rinsed with ultra-pure water and at
a depth of at least one meter as grab samples. Samples were kept
at 4 ◦C during the transport to the laboratory. Sampling frequency
was determined taking into account the bathingwater quality, thus
the excellent samples were collected monthly; for good every two
weeks, and for sufﬁcient bathing water quality every week. Upon
reception in the laboratory, samples were vacuum ﬁltered through
1.2m glass microﬁber ﬁlters (GF/C, Whatman, UK), followed
by 0.22m nylon membrane ﬁlters and stored at −20 ◦C, until
extraction.
2.3. Solid phase extraction
The optimized SPE procedure used Strata-X cartridges (200mg,
3mL) from Phenomenex (USA) conditioned with 5mL of methanol
followed by 5mL of ultra-pure water and 5mL of ultra-pure water
at pH 2. 500mL of seawater, with pH adjusted to 2 with con-
centrated HCl, was percolated through the cartridge. Afterwards
the cartridge was rinsed with 5mL of ultra-pure water, and then
dried under vacuum for 1h to remove the excess of water. Elution
was performed with 10mL of methanol. Extracts were evaporated
under a gentle stream of nitrogen and reconstituted with 1mL
of acetonitrile–ultra-pure water (30:70, v/v). Finally, 10L of an
ibuprofen-d3 standard solution was added to obtain a ﬁnal con-
centration of 50mg/L in the extract of the internal standard.
2.4. Liquid chromatography
Chromatographic separation was carried out with a
UHPLC–MS/MS system consisting of a Shimadzu LCMS-8030
triple-quadrupole mass spectrometer (Shimadzu Corporation,
Kyoto, Japan) operated in the electrospray ionization (ESI) mode,
and a Shimadzu Nexera UHPLC system (Shimadzu Corporation,
Kyoto, Japan) which consisted of two solvent delivery modules
LC-30 AD, a column oven CTO-20 AC, and an autosampler SIL-30
Table 1
Chemical structures and physicochemical properties of the selected pharmaceuticals.
Compound Chemical structure Formula Molecular
weight
(g/mol)
pKac LogPc
Dipyrone C13H16N3NaO4S 333.37 4.85 −0.82
Acetaminophen glucuronidea C14H17NO8 327.29 3.17; 12.22 −1.04
Acetylsalicylic acid C9H8O4 180.16 3.41 1.24
Acetaminophen C8H9NO2 151.16 9.46 0.91
Carboxyibuprofena C13H16O4 236.26 3.97d 2.78d
Hydroxyibuprofena C13H18O3 222.28 4.63d 2.37d
p-Aminophenolb C6H7NO 109.13 5.43; 10.40 0.84
Ketoprofen C16H14O3 254.28 3.88 3.61
Naproxen C14H14O3 230.26 4.19 2.99
Nimesulide C13H12N2O5S 308.31 6.86 1.79
Diclofenac C14H11Cl2NO2 296.15 4.00 4.26
Ibuprofen C13H18O2 206.28 4.85 3.84
a Metabolite.
b Degradation product.
c Adapted from Ref. [28].
d Ref. [29].
Table 2
UHPLC–ESI–MS/MS conditions for the selected pharmaceuticals.
Compound Rt (min) Precursor
ion (m/z)
Product ion (quantiﬁer) Product ion (qualiﬁer) Ion ratio (± SD)
(n=6)
Q3 Q1
Pre bias
(V)
CE
(V)
Q3
Pre bias
(V)
Q3 Q1
Pre bias
(V)
CE
(V)
Q3
Pre bias
(V)
Dipyrone 1.05 310.30 191.05 16 15 21 80.05 16 35 16 2.78 ± 0.03
Acetaminophen glucuronidea 1.07 326.30 112.95 16 15 24 149.90 16 27 16 2.18 ± 0.01
Acetylsalicylic acid 1.51 179.20 136.85 22 10 29 93.15 22 22 19 1.87 ± 0.03
Acetaminophen 1.56 150.20 107.15 14 18 21 – – – – –
Carboxyibuprofena 2.68 235.30 191.20 12 8 14 72.90 12 17 15 1.39 ± 0.02
Hydroxyibuprofena 2.72 221.30 177.15 11 8 21 – – – – –
p-Aminophenolb 3.30 151.00 109.85 −16 −10 −23 64.95 −16 −32 −24 3.98 ± 0.11
Ketoprofen 3.90 253.30 208.90 13 8 23 – – – – –
Naproxen 3.96 229.10 169.90 10 17 19 169.05 10 35 18 1.01 ± 0.01
Nimesulide 4.11 307.00 229.10 10 18 16 79.10 10 29 16 7.63 ± 0.05
Diclofenac 4.34 294.20 249.85 14 12 18 34.90 14 24 13 13.04 ± 0.04
Ibuprofen-d3 4.46 207.50 164.25 13 10 18 – – – – –
Ibuprofen 4.48 205.30 161.20 13 10 18 – – – – –
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a Metabolite.
b Degradation product.
C. The system was controlled by a system controller CBM-20A.
ab Solutions software (Shimadzu Corporation, Kyoto, Japan)
as used for control and data processing. A Kinetex C18 column
2.6mm×150mm i.d.; 1.7m particle size) (Phenomenex, USA)
as used. The optimized separation conditions were achieved
sing ultra-pure water as solvent A and acetonitrile as solvent B
t a ﬂow rate of 0.22mL/min. The gradient elution was performed
s follows: initial conditions: 30% B; 0–1.0min, 30–35.6% B;
.0–2.0min, 35.6–100% B; 2.0–6.0min, 100% B; 6.0–6.5min, return
o initial conditions; 6.5–10.5min, equilibration of the column. The
njection volume was 5L and column oven was set at 30 ◦C. The
utosampler was operated at 4 ◦C and the autosampler needle was
insed before and after aspiration of the sample using acetonitrile.
MS settings were analyte-speciﬁc and were optimized by direct
njection of individual standard solutions of each compound at
0mg/L. Pharmaceuticals were analyzed in the negative ESI mode,
ith the exception of p-aminophenol that was analyzed in the pos-
tive mode. Mass spectrometer was operated in multiple reaction
onitoring mode (MRM) and two MRM transitions were moni-
ored for each compound, being themost intense used as quantiﬁer
nd the second one as qualiﬁer. In the case of acetaminophen,
ydroxyibuprofen, ketoprofen, ibuprofen and ibuprofen-d3 only
ne transition could be recorded due to their poor fragmenta-
ion [32]. A summary of individual MS/MS parameters is shown
n Table 2. A dwell time of 25ms was used for all compounds.
Source-dependent parameters were also optimized by direct
njection, using a standard mixture solution at 10mg/L, and are
s follows: nebulizing gas (nitrogen) and drying gas (nitrogen) at a
ow rate of 2.6 and 12.5 L/min, respectively; interface voltage was
et at 5.0 kV; desolvation temperature was 250 ◦C, and heat block
emperature was 300 ◦C. Argon was used as the collision induced
issociation gas (CID) at a pressure of 230kPa.
.5. Method validation
The performance of themethodwas evaluated through the esti-
ation of the linearity, extraction recoveries, method detection
MDL) and quantiﬁcation limits (MQL), precision (intra- and inter-
ay), and matrix effects.Recoveries were determined by comparing the concentrations
btained, calculated by internal standard calibration, with the
nitial spiking levels. For each recovery test, blanks (no-spiked sam-
les) were analyzed in order to determine their concentrations,which were afterwards subtracted to the spiked seawater samples.
Matrix effects were also evaluated.
The precision of the method was determined by repeated intra-
day and inter-day analysis (six successive injections of a 100g/L
standard solution with all the analytes in one day and in ﬁve suc-
cessive days, respectively), expressing it as the relative standard
deviation (RSD) of these replicate measurements.
Method detection limits (MDL) and method quantiﬁcation lim-
its (MQL) were determined as the minimum detectable amount of
analytewith a signal-to-noise of 3.3 and 10, respectively.MDLs and
MQLs have been calculated as the average of those estimated in real
samples and in spiked samples.
Calibration curves were generated using linear regression anal-
ysis and over the established concentration points ranging from
0.1 to 1000g/L, depending on the compounds. Quantiﬁcation of
target analytes was performed by the internal standard approach.
Calibration standards were measured at the beginning and at the
end of each sequence, and one calibration standard was measured
repeatedly throughout the sequence to check the signal stability.
Matrix effects were assessed in order to evaluate the degree
of ion suppression or enhancement, and to what extent target
compounds were sensitive to them. Matrix effects were calculated
according to Eq. (1) by dividing the slopes of the matrix-matched
calibrationcurvesprepared in seawater (slopematrix-matched) and the
slopes of the calibration curves prepared in solvent (slopesolvent). A
value of 100% indicates that there is no matrix effect, while for val-
ueshigher than100% there is ionenhancement and for lower values
(<100%) there is ion suppression.
Matrix effect (%) =
(
slopematrix−matched
slopesolvent
)
× 100 (1)
3. Results and discussion
3.1. Ultra-high performance liquid chromatography–tandem
mass spectrometry (UHPLC–MS/MS)
3.1.1. Chromatographic separation
In order to optimize the chromatographic separation and sensi-
tivity of the studied analytes, differentmobile phases and additives
were tested. Acetonitrile,methanol ormixtures of bothwere tested
as organic phase while non-buffer ultra-pure water and buffers
such ammonium formate, ammonium acetate and addition of 0.1%
formic acid were evaluated as mobile phase for the aqueous phase.
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Fig. 1. Representative chromatograms of the MRM transition used for quantiﬁca-
tion of a 100g/L standard mixture of the studied pharmaceuticals. (a) Dipyrone;
(b) acetaminophen glucuronide; (c) acetylsalicylic acid; (d) acetaminophen; (e)
carboxyibuprofen; (f) hydroxyibuprofen; (g) p-aminophenol; (h) ketoprofen; (i)
naproxen; (j) nimesulide; (k) diclofenac; (l) ibuprofen; and (m) ibuprofen-d3.he best separation was achieved using acetonitrile and ultra-pure
ater, since this mobile phase provided better resolution, peak
hape and sensitivity for the studied pharmaceuticals.
Once the mobile phase composition was established, the mode
f elution (isocratic or gradient elution), as well as the ﬂow rate
ere optimized with the aim to improve chromatographic resolu-
ion and peak shapes and simultaneously to reduce total analysis
ime. The optimum ﬂow rate was set to 0.22mL/min. Further-
ore, different oven temperatures (25, 30, 32, 35 and 38 ◦C) were
ested. Peak shape and chromatographic response improved when
0 ◦C was used. A chromatogram of a standard solution under the
ptimized conditions is presented in Fig. 1. As can be seen, the sep-
ration of analytes is not complete, what is not necessary for the
electiveMS/MSdetection,which allows an improved detectability
nd a reduction in ion suppression effect [33].
.1.2. Mass spectrometry (MS/MS)
The precursor ion for each analyte was selected by recording
hromatograms in full scan mode. From the 12 pharmaceuticals
tudied in this work, all showed higher response in negative elec-
rospray ionization mode, with the exception of p-aminophenol
or which positive electrospray ionization was more sensitive.
n general, [M−H]− was chosen for precursor ion for negative
onization with the exception of dipyrone, which precursor ion
as [M−Na]−. p-Aminophenol was the only compound analyzed
nder positive ionization and the adduct formed with acetonitrile
resent in the mobile phase ([M+CH3CN+H]+) was chosen as pre-
ursor ion. Formost of pharmaceuticals, twoMRMweremonitored
etween the precursor ion and the most abundant product ions
or each compound, being the ﬁrst transition used for quantiﬁca-
ion and the second one for identiﬁcation purposes. In the case of
cetaminophen, ibuprofen and hydroxyibuprofen only one MRM
ould be monitored due to their poor fragmentation. Since the iso-
opically labeled internal standard (ibuprofen-d3) is not likely to
e found in the environment, only one MRM was also monitored
Table 2).
Ionization parameters like drying and nebulizing gas ﬂow rates,
eat block and desolvation temperatures and interface voltage
re key parameters to obtain higher sensitivity; therefore these
arameters were also optimized. The nebulizing gas ﬂow rate was
tudied between 0.5 and 3.0 L/min and the drying gas ﬂow rate
rom 10.0 to 20.0 L/min. Higher sensitivity was observed using 2.6
nd 12.5 L/min for nebulizing gas and drying gas ﬂow rate, respec-
ively. The study of the desolvation temperature was made for
alues between 200 and 300 ◦C, while for the heat block temper-
ture values ranged from 200 to 500 ◦C. The signal of the studied
nalytes was increased when 250 and 300 ◦C were used for desol-
ation and heat block temperatures, correspondingly. Finally, the
nterface voltage was tested between 0.5 and 5.0 kV, showing that
he higher the interface voltage the greater was the sensitivity for
ll analytes.
.2. Solid phase extraction optimization
Usually SPE is the technique of choice for the extraction of
harmaceuticals from water samples [17]. Therefore, a SPE proce-
urewasdeveloped for theanalysis of the selectedpharmaceuticals
n seawater. Different parameters were studied, namely type of
orbent, sample’s pH and sample’s volume, in order to evaluate
hich conditions yielded higher recoveries of the target pharma-
euticals. The SPE method was optimized using ultra-pure water
nd seawater.Preliminary studies were made to evaluate the performance of
ifferent SPE sorbents according to the variation of sample’s pH.
or that, the extraction efﬁciency of the polymeric reversed phase
trata-X (200mg, 3mL), the mixed-mode reversed phase/anionic
Fig. 2. Recoveries obtained for the target analytes with different SPE cartridges, using different sample’s pH. (a) Strata-X; (b) Strata X-AW; (c) Strata X-A; and (d) Strata X-C.
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trata X-C (200mg, 3mL) was studied at different sample’s pH
pH 2, without pH adjustment and pH 7). The obtained results are
resented in Fig. 2. In general, for most of studied pharmaceut-
cals, similar recoveries were yielded with the tested SPE sorbents,
hough Strata X-A showed lower values and it did not allow recov-
ring acetaminophen glucuronide (Fig. 2C). On the other hand,
-aminophenol was never recovered with any of the sorbents,
hereas dipyrone was only extracted with Strata X-AW, but with
low efﬁciency (36%) (Table S1, Supplementary material). Since
ipyrone is negatively charged at all pH range, this analyte was
ble to establish ionic interactions with the sorbent material (a
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ode reversed phase/weak anionic exchange sorbent Strata X-AW
howed higher recovery values for NSAIDs for a sample’s pH of 7
Fig. 2B). This is in agreementwithNSAIDspKa values (pKabetween
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tively charged (Table S2, Supplementary material), establishing
onic interactions with the diamine groups present in the sor-
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egative charge, sharing the extraction by ionic interactions with
SAIDs. On the other hand, acetaminophen is in its neutral form
Table S2, Supplementary material) and was extracted by reversedphase mechanisms. Although Strata X-AW showed a good extrac-
tion efﬁciency, Strata-X achieved a better performance, with RSD
values between 1.2% (acetaminophen) and 9.5% (acetaminophen
glucuronide), when sample pH was adjusted to 2, together with
high recovery values (Fig. 2, Table S1 Supplementary material).
Strata-X is a polymeric sorbent with a styrenic skeleton chemically
modiﬁed with a pyrrolidone group [35] and pharmaceuticals were
extracted through reversed phase mechanisms and – interac-
tions, since at the selected pH NSAIDs are in their neutral form
(Table S2, Supplementary material). Therefore, the protocol based
on Strata X cartridges was chosen for further studies, because it
showed to be more suitable for the extraction of a greater num-
ber of pharmaceuticals with a better performance and higher
recoveries.
The sample volume was also studied and the breakthrough SPE
volume was determined using 50, 100, 250, 500, and 1000mL of
ultra-pure water. For most of the studied compounds recovery val-
ues maintained constant for sample volumes up to 500mL, being
observed a decrease for higher volumes, whereas for acetylsalicylic
acid the recovery remained constant for all the studied volumes.
However, for acetaminophen and acetaminophen glucuronide, it
was observed a decrease in the recovery values with increasing
sample volumes. In this way, and attending that pharmaceuticals
have been found in seawater at low levels (few ng/L) [20,22], a
sample volume of 500mL was chosen, because it would allow to
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.etter concentrate pharmaceuticals present in real samples and
imultaneously to get higher recoveries for most of the studied
SAIDs/analgesics.
.3. Method validation
Since it was not possible to recover p-aminophenol, dipyrone
nd acetaminophen glucuronide under the optimized SPE condi-
ions, these compoundswere not considered formethod validation
urposes.
The performance of the developed method was validated in
erms of sensitivity, linearity, recoveries, precision (intra- and
nter-day) and matrix effects, using seawater. Detailed analytical
uality assurance data is shown in Table 3.
Accuracy of the method was estimated from recovery exper-
ments of the target analytes at different concentrations. Thus,
hree fortiﬁcation levels (0.2, 0.5, and 1g/L) were tested. The
ecoveries obtained varied from 11.2% for acetaminophen to 101%
or naproxen and ketoprofen (Table 3). Linearity was studied in
he concentration ranges presented in Table 3 with correlation
oefﬁcients (r2) higher than 0.99. Depending on the sensitivity of
ach analyte different linear responses were obtained. The preci-
ion of the method was evaluated in terms of precision (intra and
nter-day), exhibiting RSD values below 4.48% and 8.10%, respec-
ively. MDLs and MQLs ranged from 0.02 (naproxen) to 8.18ng/L
carboxyibuprofen) and 0.06 (naproxen) to 24.8ng/L (carboxy-
buprofen), respectively. The potential interferences of the matrix
n the measurements were evaluated. For the studied NSAIDs, all
ompounds showed ion enhancement, being the effect more pro-
ounced for pharmaceuticals like ibuprofen and nimesulide. In
rder to correct the matrix effect and avoid inaccurate quantiﬁ-
ation, an isotopically labeled standard was used. This approach
as been identiﬁed as a very powerful tool to compensate adverse
atrix effects observed with ESI for the analysis of aqueous matri-
es [20]. Therefore, in this study, internal standard calibrationusing
he isotopically labeled standard ibuprofen-d3 was used as the
trategy to correct matrix effects. It should be kept in mind that the
election of an internal standard has to be based on its similarity
ith the compounds of interest, for what concerns to mass spec-
rometric response, chemical structure, chromatographic retention
ime and matrix effect (ion suppression or enhancement) [20].
.4. Application to seawater samples
The developed method was applied to seawater samples of
tlanticOcean collected in theNorth of the Portuguese coast during
he 2013 bathing season. Ten samples from three beaches with dif-
erent bathingwater quality, namely excellent, good, and sufﬁcient
ere collected and analyzed.
Results obtained are summarized in Fig. 3. All the pharma-
euticals were detected at least in one seawater sample. The
harmaceuticals ibuprofen, hydroxyibuprofen, acetaminophen
nd ketoprofen had a frequency of detection of 100%, while for
he remaining NSAIDs the frequency of detection varied from
0% (carboxyibuprofen, acetylsalicylic acid and nimesulide) to 30%
naproxen). The concentrations detected for the different pharma-
euticals varied from 0.46ng/L for nimesulide to 600.5ng/L for
arboxyibuprofen, being the highest concentrations reported for
buprofen and its metabolites and acetaminophen (Fig. 3), two
harmaceuticals with a high consumption rate among Portuguese
opulation [25]. In general, these highest concentrations were
etected in the Azul (Conchinha) beach,whose bathingwater qual-
ty is classiﬁed as sufﬁcient. On the other hand, nimesulidewas only
etected in the excellent bathing water beach (Lec¸a da Palmeira)
Fig. 3). Ta
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0Fig. 3. Concentration of NSAIDs/analgesics,
The presence of pharmaceuticals belonging to NSAIDs and anal-
esics had also been reported in the Mediterranean Sea [20,23],
hough at lower levels than those reported herein, while Wu et al.
2010) [24] found similar concentrations of naproxen, diclofenac
nd ibuprofen in Marine Bay (Singapore). On the other hand, the
SAIDs and analgesics selected in this study were not detected
n the Baltic Sea [19] or in the North Sea [22]. Nödler et al.
22] quantiﬁed several pharmaceuticals, such as carbamazepine,
affeine, clarithromycin, and sulfamethoxazole, in a sample col-
ected in the Baltic Sea (Ahlbeck, Usedom). Levels up to 58ng/L
ere found for the pharmaceuticals with the maximum level
eing observed for caffeine. The NSAIDs included in the referred
tudy, namely, diclofenac, ibuprofen, naproxen, acetaminophen,
nd phenazone were not detected in the analyzed seawater sam-
le despite the low method quantitation limits (MQLs) in the range
.0–4.8ng/L.
Wille et al. [22] reported a LC–MS/MS method for the simulta-
eous quantiﬁcation of 13 pharmaceuticals, including the NSAIDs
alicylic acid, ketoprofen and diclofenac. Salicylic acid was found in
levenout of twelve samples collected in three locations of Belgium
oast, in the period 2007–2009, in concentrations up to 660ng/L.
he LOQs for ketoprofen and diclofenac were 50ng/L, which were
igniﬁcantly higher than the ones obtained in our study (0.90 and
.06ng/L, respectively).ssed in ng/L, detected in seawater samples.
Relatively to ibuprofen metabolites, carboxyibuprofen is its
humanmetabolitewith the highest percentage of excretion [29,36]
therefore it is more probable to be found in the environment
thanhydroxyibuprofen and ibuprofen. However, contrarily towhat
was expected, carboxyibuprofen was only detected in one sam-
ple from Azul (Conchinha) beach (Fig. 3), being hydroxyibuprofen
the metabolite most frequently detected in seawater. Similar
ﬁndings have been reported in different environmental aqueous
matrices [29,37]. Thus, it could be concluded that hydroxyibupro-
fen might be a more stable metabolite than carboxyibuprofen,
which also showed a higher removal rate comparatively to other
ibuprofen metabolites in batch experiments [29,37]. However,
when ibuprofen and its two main metabolites were detected in
the same sample (sampling day 09/07/2013), carboxyibuprofen
showedhigher concentrations (600.5ng/L). The samebehaviorwas
observed in seawater samples from the Breivika Harbor (Norway)
[37] aswell as in Ter river (Spain) [29], althoughwhile in the former
levels did not exceed 5.3ng/L, in the river samples carboxyibupro-
fen reach concentrations of 3.95g/L.4. Conclusions
A new analytical method based on off-line SPE–UHPLC–MS/MS
was developed to determine the presence of pharmaceuticals
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[elonging to NSAIDs and analgesics therapeutic groups in seawa-
ers. UHPLC technology was used in order to obtain faster analysis,
eduction in solvent consumption and a higher sample through-
ut. MS/MS detection was applied to get better sensitivity and
more precise identiﬁcation of the studied pharmaceuticals in
complex matrix as seawater, since two MRM transitions were
onitored for most of compounds. The present method allowed
chieving MDLs in the low ng/L range, proving to be a robust
nd reliable tool for monitoring pharmaceuticals in environmental
amples.
The developed method was successfully applied to the analy-
is of seawater samples from the Atlantic Ocean collected in the
orth of the Portuguese coast. The results revealed thatNSAIDs and
nalgesics are widespread in seawater, being ibuprofen, hydrox-
ibuprofen, acetaminophen and ketoprofen detected in all the
amples. The concentrations found ranged from 0.46 to 600.5ng/L
or nimesulide and carboxyibuprofen, respectively, and it was
roved the importance of including human metabolites in analyt-
cal methods, given that they might be at higher levels than the
arent compound, as was demonstrated by the analysis of ibupro-
en and its main human metabolites.
The described method could be a useful tool to be used in mon-
toring studies in order to evaluate the occurrence and fate of
harmaceuticals (NSAIDs and analgesics) in seawaters as well as
o help in the identiﬁcation of possible sources of contamination of
arine environments.
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